Intended for healthcare professionals


US drug labels to warn of risks of combining opioids and benzodiazepines

BMJ 2016; 354 doi: (Published 02 September 2016) Cite this as: BMJ 2016;354:i4784
  1. Michael McCarthy
  1. Seattle

The US Food and Drug Administration is demanding changes to the labels for prescription opioid and benzodiazepine products to include warnings of the risks of profound sedation, respiratory suppression, coma, and death when these drugs are used in combination.1

FDA commissioner Robert Califf said that the agency was taking the action in response to the substantial increase in overdoses seen in patients taking opioids and benzodiazepines together. He said, “We implore healthcare professionals to heed these new warnings and more …

View Full Text

Log in

Log in through your institution


* For online subscription